Pneumocystis Pneumonia

Shelley A. Gilroy; Nicholas J. Bennett

doi:10.1055/s-0031-1295725

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2011; 32(6): 775-782
DOI: 10.1055/s-0031-1295725

Pneumocystis Pneumonia

Shelley A. Gilroy¹ , Nicholas J. Bennett² ^, ³

¹Division of Infectious Disease/HIV Medicine, Albany Medical College, Albany, New York
²Department of Pediatrics, State University of New York Upstate Medical University, Syracuse, New York
³current affiliation: Division of Infectious Diseases, Connecticut Children's Medical Center, Hartford, Connecticut

Abstract

ABSTRACT

Pneumocystis (carinii) jiroveci pneumonia can occur in immunocompromised individuals, especially hematopoietic stem and solid organ transplant recipients and those receiving immunosuppressive agents, and is the most common opportunistic infection in persons with advanced human immunodeficiency virus (HIV) infection. The Pneumocystis genus was initially mistaken as a trypanosome and later as a protozoan. Genetic analysis identified the organism as a unicellular fungus. Pneumocystis jiroveci is the species responsible for human infections. A slow indolent time course with symptoms of pneumonia progressing over weeks to months is characteristic in HIV-infected patients. Fulminant respiratory failure associated with fever and dry cough is typical in non-HIV-infected patients. Definitive diagnosis relies on histopathological testing of sputum, induced or sampled by fiberoptic bronchoscopy with bronchoalveolar lavage. The first-line drug for treatment and prevention is trimethoprim-sulfamethoxazole.

KEYWORDS

Pneumocystis pneumonia - trimethoprim-sulfamethoxazole - Pneumocystis jiroveci

Full Text

References

REFERENCES

1 Stringer J R, Beard C B, Miller R F, Wakefield A E. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002; 8 (9) 891-896
2 Kovacs J A, Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA. 2009; 301 (24) 2578-2585
3 Schmoldt S, Schuhegger R, Wendler T et al.. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol. 2008; 46 (3) 966-971
4 de Boer M G, Bruijnesteijn van Coppenraet L E, Gaasbeek A et al.. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source?. Clin Infect Dis. 2007; 44 (9) 1143-1149
5 Sepkowitz K A. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis. 2002; 34 (8) 1098-1107 Erratum in: Clin Infect Dis 2002 1:34(9):1293
6 Centers for Disease Control and Prevention (CDC). HIV/AIDS Surveillance Supplemental Report, vol 9, no. 3. Atlanta, GA: Centers for Disease Control and Prevention; 2003: 1-20
7 Thomas Jr C F, Limper A H. Pneumocystis pneumonia. N Engl J Med. 2004; 350 (24) 2487-2498
8 Edman J C, Kovacs J A, Masur H, Santi D V, Elwood H J, Sogin M L. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988; 334 (6182) 519-522
9 Cushion M T, Stringer J R. Has the name really been changed? It has for most researchers. Clin Infect Dis. 2005; 41 (12) 1756-1758
10 Gigliotti F. Pneumocystis carinii: has the name really been changed?. Clin Infect Dis. 2005; 41 (12) 1752-1755
11 Gigliotti F, Harmsen A G, Haidaris C G, Haidaris P J. Pneumocystis carinii is not universally transmissible between mammalian species. Infect Immun. 1993; 61 (7) 2886-2890
12 Ponce C A, Gallo M, Bustamante R, Vargas S L. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis. 2010; 50 (3) 347-353
13 Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis. 2008; 197 (1) 10-17
14 Fischl M A, Dickinson G M, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA. 1988; 259 (8) 1185-1189
15 Walzer P D, Perl D P, Krogstad D J, Rawson P G, Schultz M G. Pneumocystis carinii pneumonia in the United States: epidemiologic, diagnostic, and clinical features. Ann Intern Med. 1974; 80 (1) 83-93
16 Morris A, Lundgren J D, Masur H et al.. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis. 2004; 10 (10) 1713-1720
17 Murray J F. Pulmonary complications of HIV-1 infection among adults living in Sub-Saharan Africa. Int J Tuberc Lung Dis. 2005; 9 (8) 826-835
18 Yale S H, Limper A H. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996; 71 (1) 5-13
19 Bollée G, Sarfati C, Thiéry G et al.. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest. 2007; 132 (4) 1305-1310
20 Sepkowitz K A, Brown A E, Telzak E E, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992; 267 (6) 832-837
21 De Castro N, Neuville S, Sarfati C et al.. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant. 2005; 36 (10) 879-883
22 Radisic M, Lattes R, Chapman J F et al.. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis. 2003; 5 (2) 84-93
23 Harigai M, Koike R, Miyasaka N. Pneumocystis Pneumonia under Anti-Tumor Necrosis Factor Therapy (PAT) Study Group . Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007; 357 (18) 1874-1876
24 Kaplan J E, Benson C, Holmes K H, Brooks J T, Pau A, Masur H. Centers for Disease Control and Prevention (CDC) . Guidelines for prevention and treatment of opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009; 58 (RR-4) 1-207, quiz CE1–CE4
25 Shelburne III S A, Hamill R J, Rodriguez-Barradas M C et al.. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002; 81 (3) 213-227
26 French M A, Lenzo N, John M et al.. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 2000; 1 (2) 107-115
27 Stover D E, Greeno R A, Gagliardi A J. The use of a simple exercise test for the diagnosis of Pneumocystis carinii pneumonia in patients with AIDS. Am Rev Respir Dis. 1989; 139 (6) 1343-1346
28 Boiselle P M, Crans Jr C A, Kaplan M A. The changing face of Pneumocystis carinii pneumonia in AIDS patients. AJR Am J Roentgenol. 1999; 172 (5) 1301-1309
29 Gruden J F, Huang L, Turner J et al.. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR Am J Roentgenol. 1997; 169 (4) 967-975
30 Coleman D L, Hattner R S, Luce J M, Dodek P M, Golden J A, Murray J F. Correlation between gallium lung scans and fiberoptic bronchoscopy in patients with suspected Pneumocystis carinii pneumonia and the acquired immune deficiency syndrome. Am Rev Respir Dis. 1984; 130 (6) 1166-1169
31 Raviglione M C. Extrapulmonary pneumocystosis: the first 50 cases. Rev Infect Dis. 1990; 12 (6) 1127-1138
32 Shelhamer J H, Gill V J, Quinn T C et al.. The laboratory evaluation of opportunistic pulmonary infections. Ann Intern Med. 1996; 124 (6) 585-599
33 Bigby T D. Diagnosis of Pneumocystis carinii pneumonia. How invasive?. Chest. 1994; 105 (3) 650-652
34 Broaddus C, Dake M D, Stulbarg M S et al.. Bronchoalveolar lavage and transbronchial biopsy for the diagnosis of pulmonary infections in the acquired immunodeficiency syndrome. Ann Intern Med. 1985; 102 (6) 747-752
35 Armbruster C, Pokieser L, Hassl A. Diagnosis of Pneumocystis carinii pneumonia by bronchoalveolar lavage in AIDS patients: comparison of Diff-Quik, fungifluor stain, direct immunofluorescence test and polymerase chain reaction. Acta Cytol. 1995; 39 (6) 1089-1093
36 Kovacs J A, Ng V L, Masur H et al.. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med. 1988; 318 (10) 589-593
37 Wakefield A E, Guiver L, Miller R F, Hopkin J M. DNA amplification on induced sputum samples for diagnosis of Pneumocystis carinii pneumonia. Lancet. 1991; 337 (8754) 1378-1379
38 Larsen H H, Masur H, Kovacs J A et al.. Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol. 2002; 40 (2) 490-494
39 Azoulay E, Bergeron A, Chevret S, Bele N, Schlemmer B, Menotti J. Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest. 2009; 135 (3) 655-661
40 Boldt M J, Bai T R. Utility of lactate dehydrogenase vs radiographic severity in the differential diagnosis of Pneumocystis carinii pneumonia. Chest. 1997; 111 (5) 1187-1192
41 Desmet S, Van Wijngaerden E, Maertens J et al.. Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol. 2009; 47 (12) 3871-3874
42 Safrin S, Finkelstein D M, Feinberg J et al.. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med. 1996; 124 (9) 792-802
43 Kovacs J A, Gill V J, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA. 2001; 286 (19) 2450-2460
44 Fishman J A. Treatment of infection due to Pneumocystis carinii. Antimicrob Agents Chemother. 1998; 42 (6) 1309-1314
45 Noskin G A, Murphy R L, Black J R, Phair J P. Salvage therapy with clindamycin/primaquine for Pneumocystis carinii pneumonia. Clin Infect Dis. 1992; 14 (1) 183-188
46 Smego Jr R A, Nagar S, Maloba B, Popara M. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch Intern Med. 2001; 161 (12) 1529-1533
47 Queener S F, Bartlett M S, Richardson J D, Durkin M M, Jay M A, Smith J W. Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother. 1988; 32 (6) 807-813
48 Helweg-Larsen J, Benfield T, Atzori C, Miller R F. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother. 2009; 64 (6) 1282-1290
49 Medina I, Mills J, Leoung G et al.. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med. 1990; 323 (12) 776-782
50 Walzer P D, Smulian G A. Pneumocystis species. In: Mandell G L, Bennett J E, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2010: 3385
51 Klein N C, Duncanson F P, Lenox T H et al.. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS. 1992; 6 (3) 301-305
52 Bozzette S A. The use of corticosteroids in Pneumocystis carinii pneumonia. J Infect Dis. 1990; 162 (6) 1365-1369
53 Bozzette S A, Sattler F R, Chiu J California Collaborative Treatment Group et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990; 323 (21) 1451-1457
54 Wagner K R, Chaisson R E. Pulmonary complications of HIV infection. In: Wormser G P, ed. AIDS and Other Manifestations of HIV Infection. 4th ed. Milan, Italy: Elsevier Academic; 2004: 411
55 Helweg-Larsen J, Benfield T L, Eugen-Olsen J, Lundgren J D, Lundgren B. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet. 1999; 354 (9187) 1347-1351
56 Takahashi T, Hosoya N, Endo T et al.. Relationship between mutations in dihydropteroate synthase of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance to sulfonamide therapy. J Clin Microbiol. 2000; 38 (9) 3161-3164
57 Nahimana A, Rabodonirina M, Helweg-Larsen J et al.. Sulfa resistance and dihydropteroate synthase mutants in recurrent Pneumocystis carinii pneumonia. Emerg Infect Dis. 2003; 9 (7) 864-867
58 Huang L, Crothers K, Atzori C et al.. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerg Infect Dis. 2004; 10 (10) 1721-1728
59 Navin T R, Beard C B, Huang L et al.. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study. Lancet. 2001; 358 (9281) 545-549
60 Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2007; (3) CD005590. doi:10.1002/14651858.CD005590
61 Sepkowitz K A. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should receive prophylaxis?. Mayo Clin Proc. 1996; 71 (1) 102-103
62 Velayos F S, Sandborn W J. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis. 2004; 10 (5) 657-660

Shelley A. GilroyM.D.

Division of Infectious Disease/HIV Medicine, Albany Medical College

47 New Scotland Ave. MC 158, Albany, NY 12208

Email: gilroys@mail.amc.edu